Stock hit ₹648.3 on April 6, up 5.59% that day, way ahead of the sector. It's trading above all key moving averages—5-day to 200-day—like a car cruising past traffic. MACD screams bullish on weekly charts too. But hey, RSI looks a bit overbought short-term; could mean a quick breather. Pharma's hot from US policy wins and export booms, think generics dodging price squeezes.
Key Numbers at a Glance:
Market cap sits around ₹14,429 crore. P/E is 26.5, below pharma industry's 33-ish average—looks decent value. ROE? Solid 14.52% last year. Debt-to-equity is low at 0.35—company's not drowning in loans. Cash flow? Operating cash jumped to ₹867 crore in FY25 from ₹439 crore prior—healthy sign they're generating real money. Dividend yield's tiny, like 0.27%, not for income hunters. Profit growth? PAT up 24% YoY to ₹502 crore in FY25. Q3 FY26 net profit climbed 28% to ₹150 crore too. Numbers say stable, not explosive, but improving.
Started in 1984 by Krishna Prasad Chigurupati and wife Uma in Hyderabad as Triton Labs. Focused on paracetamol APIs first. Now a vertically integrated player—makes APIs, intermediates (PFIs), and finished dosages (FDs) like tablets. Exports to 60+ countries, 81% revenue from outside India. Business model? Control the whole chain from raw ingredients to pills—cuts costs, dodges supply hiccups. Like baking your own bread instead of buying slices. Products hit regulated markets like US, Europe.
Short-term, riding this rally?
Could test ₹670 by end-2026 if pharma keeps humming. 2030? Analysts eye ₹720-900, assuming 10% CAGR like sector. But 2035 or 2040? Tough call—pharma grows steady, but competition bites. I'd guess ₹1,500 by 2035 if exports double, ₹3,000+ by 2040 on global demand. Pure extrapolation though; markets hate predictions. Remember 2020 crash? One bad FDA nod tanks it.
